| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
One biological target for the treatment of alcohol misuse and dependence is the brain's nicotinic acetylcholine receptors (nAChRs), a diverse family of pentameric acetylcholine-gated cation channels[1].
|
|---|---|
| ln Vivo |
UFR2709 significantly and dose-dependently reduces bottom dwelling time to 52.9 and 87.0 s, respectively, at 50 and 100 μg/ml. (S)-UFR2709 (hydrochloride) (50-100 μg/ml; 3 min and then maintained for another 5 min in a holding tank before testing the swimming behavior in the test tank for a period of 5 min[2]). (S)-UFR2709 (hydrochloride) (50-100 μg/ml) reduces the α4 nACh receptor subunit's nicotine-evoked mRNA expression, although UFR2709 has less of an impact on the subunit in the adult zebrafish brain[2]. In a dose-dependent manner, intraperitoneal injection of (S)-UFR2709 (hydrochloride; 1- 10 mg/kg; daily; 17 days) increases water consumption while decreasing ethanol consumption and preference. UFR2709's most potent dosage is 2.5 mg/kg, which results in a 56% decrease in alcohol intake. (S)-UFR2709 (hydrochloride) has no effect on the rats' body weight or level of locomotor activity[1].
|
| Animal Protocol |
Animal/Disease Models: High-alcohol-drinking UChB rats[1]
Doses: 10 mg/kg, 5 mg/kg, 2.5 mg/ kg, or 1 mg/kg Route of Administration: intraperitoneal (ip) injection; 1-10 mg/kg; daily; 17 days Experimental Results: Did not affect the weight or locomotor activity and decreased ethanol consumption and preference. |
| References |
| Molecular Formula |
C13H18CLNO2
|
|---|---|
| Molecular Weight |
255.740522861481
|
| Exact Mass |
255.102
|
| CAS # |
2934318-93-9
|
| Related CAS # |
(S)-UFR2709;1431628-22-6
|
| PubChem CID |
162642465
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
236
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN1CCC[C@H]1COC(=O)C2=CC=CC=C2.Cl
|
| InChi Key |
IJJHQEXZNVTJHI-YDALLXLXSA-N
|
| InChi Code |
InChI=1S/C13H17NO2.ClH/c1-14-9-5-8-12(14)10-16-13(15)11-6-3-2-4-7-11;/h2-4,6-7,12H,5,8-10H2,1H3;1H/t12-;/m0./s1
|
| Chemical Name |
[(2S)-1-methylpyrrolidin-2-yl]methyl benzoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (391.02 mM)
DMSO: 50 mg/mL (195.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (195.51 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9102 mL | 19.5511 mL | 39.1022 mL | |
| 5 mM | 0.7820 mL | 3.9102 mL | 7.8204 mL | |
| 10 mM | 0.3910 mL | 1.9551 mL | 3.9102 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
